This industry research report includes a detailed segmentation of the global GERD market by drug class (proton pumps inhibitors, H2 receptor antagonists, antacids, prokinetics, and CAM), by route of administration (oral and parenteral), and by dosage form (solid and liquids). It also outlines the market shares for key regions such as the Americas, APAC, and Europe. The top vendors analyzed in this report are AstraZeneca, Eisai, GlaxoSmithKline, Johnson & Johnson, and Takeda.
Market outlook of the global GERD market
Technavio’s market research analyst predicts the global gastroesophageal reflux disease (GERD) market to grow at a modest CAGR of more than 2% by 2020. The advent of cost-effective over-the-counter (OTC) drugs will foster the prospects for growth in this market during the forecast period. In recent times, it has been observed that many patients prefer OTC drugs as they are extremely cost effective. Since OTC drugs are not patented, their production cost is very low. This allows easy access for patients, which in turn augments the consumption of OTC drugs and decreases the incidence of withdrawal from treatment regimens.
In terms of geography, the Americas will be the highest revenue generating market segment during the forecast period. The high incidence of GERD in this region will lead to the increase in consumption of various drugs meant to treat the patients. This increase in the consumption of drugs will result in this region’s impressive market value of more than USD 4 billion by 2020.
Drug-class segmentation of the GERD market
- Proton pumps inhibitors
- H2 receptor antagonists
- Antacids
- Prokinetics
- CAM
Technavio market research analysts have estimated the antacids segment to account for more than 61% of the total market share during the forecast period. This segment consists of drugs that contain weak bases. These bases react with stomach acids to neutralize and release salt and water. The augmented use of antacid drugs like Alka-Seltzer, Maalox Advanced Regular Strength, Pepto-bismol, Rolaids, and Mylanta will result in the strong growth of this market segment during the estimated period.
Segmentation by route of administration and analysis of the GERD market
- Oral
- Parenteral
In this market research, analysts have estimated the oral route of drug administration to be the most preferred route of drug administration during the forecast period. The drugs administered through this route have to undergo first-pass metabolism and can be administered as tablets, capsules, and oral liquids. This route’s high degree of safety will result in its augmented preference during the forecast period.
Competitive landscape and key vendors
The global GERD market is highly competitive owing to the presence of numerous small and large players that operate on a local or global scale. The vendors in this market compete on the basis of price, quality, and innovation to gain maximum market traction during the forecast period.
The leading vendors in the market are -
- AstraZeneca
- Eisai
- GlaxoSmithKline
- Johnson & Johnson
- Takeda
Other prominent vendors in the market include Ahn-Gook Pharmaceutical, Cancer Advances, CJ Cheil Jedang, Daewoong Pharmaceutical, Ironwood Pharmaceuticals, RaQualia Pharma, SFJ Pharmaceuticals Group, Sucampo Pharmaceuticals, Vecta Pharmaceuticals, Wockhardt, Yuhan, and Zeria Pharmaceuticals.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global GERD market?
- What are the key market trends impacting the growth of the GERD market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the vendors in the global GERD market?
- Trending factors influencing the market shares of the Americas, APAC, and Europe?
- What are the key outcomes of the five forces analysis of the GERD market?
Technavio also offers customization on reports based on specific client requirement.